Cytomegalovirus (CMV) infection remains a serious problem in lung transplant recipients.
Development of potent oral antiviral agents, molecular techniques for the detection of …

Background. Cytomegalovirus (CMV) resistance to ganciclovir has become increasingly
common in acquired immu; nodeficiency syndrome patients but has only rarely been …

Cytomegalovirus (CMV) infection is common after lung transplantation. We performed a
prospective trial of valganciclovir prophylaxis in lung recipients with outcomes compared to …

BACKGROUND: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality
after lung transplantation despite ganciclovir prophylaxis. The emergence of ganciclovir …

Cytomegalovirus (CMV) remains the single most important pathogen following solid organ
transplantation. 1 This is perhaps no better illustrated than in clinical lung transplantation …

Background Cytomegalovirus (CMV) disease is an important cause of organ transplant-
related morbidity and mortality. During the last 5 years at our institution, prophylactic …

In the era of more aggressive immunosuppressive regimens and antiviral prophylaxis,
ganciclovir-resistant cytomegalovirus (CMV) has been recognized as an important clinical …

Cytomegalovirus (CMV) is a common opportunistic infection in lung transplant recipients.
Despite the use of early post‐operative intravenous ganciclovir, most high‐risk patients …

Background Cytomegalovirus (CMV) infection results in significant morbidity and mortality in
lung transplant recipients. Ganciclovir (GCV) has dramatically reduced complications …

BACKGROUND: Valganciclovir prophylaxis is advocated for lung transplant recipients, but
its efficacy is unknown. METHODS: Retrospective review was done of 109 donor …